KP Tissue Inc. (KPT) (TSX: KPT) reports the Q3 2021 financial and
operational results of KPT and Kruger Products L.P. (KPLP). Kruger
Products is Canada's leading manufacturer of quality tissue
products for the Consumer market (Cashmere, Purex, SpongeTowels,
Scotties, and White Swan) and the Away-From-Home (AFH) market and
continues to grow in the U.S. Consumer tissue business with the
White Cloud® brand and premium private label products. KPT
currently holds a 14.5% interest in KPLP.
KPLP Q3 2021 Business and Financial
Highlights
- Revenue increased by $22.3 million
or 6.0% to $391.4 million in Q3 2021 compared to $369.1 million in
Q3 2020.
- Adjusted EBITDA was $40.3 million
in Q3 2021 compared to $46.2 million in Q3 2020, a decrease of
12.8%, and improved sequentially from $37.3 million in Q2
2021.
- TAD Sherbrooke continues to run
above the expected start-up curve.
- Declared a quarterly dividend of
$0.18 per share to be paid on January 17, 2022
“Our solid revenue growth of 6% for the third
quarter reflects pricing actions in our Canadian Consumer segment,
combined with slightly higher volume and gradually improving
commercial end-markets, along with the execution of our recovery
plan in the Away-From-Home business. High inflationary costs and
near-record pulp prices negatively impacted our Adjusted EBITDA
compared to the same quarter last year, but the benefits of recent
price increases resulted in a sequential improvement to $40.3
million for the quarter," stated KP Tissue’s Chief Executive
Officer, Dino Bianco.
“Market share data in Canada for the most recent
52-week period further highlights the significant progress we have
made since the beginning of 2020. In our market-leading categories
we have grown bathroom tissue by 2.4 share points to 35.6% and
facial tissue increased by 4.0 share points to 35.5%. In the paper
towel category, we consolidated our strong second place through
innovations and the introduction of new products, translating into
gains of 2.6 share points to 23.2% with continued strong
investments ahead.
“The Away-From-Home segment, which was hardest
hit by the COVID-19 pandemic, showed further signs of recovery in
the quarter with 20% year-over-year revenue growth supported in
part by the faster re-opening of the U.S. economy. On the strength
of higher sales volumes, more in-house paper production and
cost-reduction initiatives, Adjusted EBITDA for this business
turned positive in Q3 2021.
“Inflationary pressure and labour shortages are
among the key challenges we will be facing in upcoming quarters. We
are executing pricing actions across the business along with a more
focused labour approach to manage our margins, while continuing to
invest to grow the top-line in both Consumer and AFH. TAD
Sherbrooke performance continues to be well ahead of our growth
curve and a key enabler for future growth,” concluded Mr.
Bianco.
OutlookWe are seeing activities
and behaviour start to return to more pre-COVID levels in both the
Consumer and Away-From-Home segments. However, cost inflation and
lagged pricing in the fourth quarter are expected to impact
results. Q4 2021 Adjusted EBITDA is therefore expected to be lower
than Q3 2021 and higher than Q4 2020.
KPLP Q3 2021 Financial
ResultsRevenue was $391.4 million in Q3 2021 compared to
$369.1 million in Q3 2020, an increase of $22.3 million or 6.0%.
The increase in revenue was due to a selling price increase in
Consumer Canada, slightly higher sales volume in the Consumer
segment compared to the year ago quarter, and an increase in sales
volume in the AFH segment resulting from the beginning of COVID-19
related demand recovery. Revenue was unfavourably impacted by
foreign exchange fluctuations on U.S. dollar sales.
Cost of sales was $345.6 million in Q3 2021
compared to $307.7 million in Q3 2020, an increase of $37.9 million
or 12.3%. Manufacturing costs increased primarily due to higher
sales volumes net of overhead absorption, increased pulp costs,
labour shortages in Memphis manufacturing, higher depreciation
expense and inflation. These increases were partially offset by the
favourable impact of more in-house paper production in AFH and
favourable foreign exchange fluctuations on U.S. dollar costs.
Freight costs and warehousing expenses also increased compared to
Q3 2020. As a percentage of revenue, cost of sales was 88.3% in Q3
2021 compared to 83.4% in Q3 2020.
Selling, general and administrative (SG&A)
expenses were $29.0 million in Q3 2021 compared to $31.2 million in
Q3 2020, a decrease of $2.2 million or 7.1%. The decrease was
primarily due to a reduction in compensation related costs, the
release of a COVID-19 related AFH accounts receivable provision
recorded during 2020 and foreign exchange gains, partially offset
by higher marketing expenses. As a percentage of revenue, SG&A
expenses were 7.4% in Q3 2021 compared to 8.5% in Q3 2020.
Adjusted EBITDA was $40.3 million in Q3 2021
compared to $46.2 million in Q3 2020, a decrease of $5.9 million or
12.8%. The decrease was primarily due to the unfavourable impact of
sales mix, higher pulp prices, inflation and higher freight rates
and warehousing costs, partially offset by the net favourable
impact of foreign exchange fluctuations and lower SG&A
expenses.
Net loss was $9.3 million in Q3 2021 compared to
net income of $18.5 million in Q3 2020, a decrease of $27.8
million. The decrease was primarily due to lower Adjusted EBITDA of
$5.9 million, and higher other, interest and depreciation expenses,
partially offset by a higher income tax recovery.
KPLP Q3 2021 Financing
ActivityTotal liquidity, representing cash and
availability under the revolving credit agreements, was $273.6
million as of September 30, 2021. In addition, $25.5 million of
cash was held for the TAD Sherbrooke Project and $24.8 million of
cash was held for the Sherbrooke Expansion Project.
KPT Q3 2021 Financial
ResultsKPT had a net loss of $2.2 million in Q3 2021.
Included in net loss was $1.4 million representing KPT’s share of
KPLP’s net loss, depreciation expense of $1.3 million related to
adjustments to carrying amounts on acquisition and an income tax
recovery of $0.4 million.
Dividends on Common SharesThe
Board of Directors of KPT declared a quarterly dividend of $0.18
per share to be paid on January 17, 2022 to shareholders of record
at the close of business on December 31, 2021.
Additional InformationFor
additional information please refer to Management’s Discussion and
Analysis (MD&A) of KPT and KPLP for the third quarter ended
September 30, 2021 available on SEDAR at www.sedar.com or our
website at www.kptissueinc.com.
Third Quarter Results Conference Call
InformationKPT will hold its third quarter conference call
on Friday, November 12, 2021 at 8:30 a.m. Eastern Time.
Via telephone: 1-800-599-5188 or
647-365-5897
Via the internet at: www.kptissueinc.com
Presentation material referenced during the
conference call will be available at www.kptissueinc.com.
A rebroadcast of the conference call will be
available until midnight, November 19, 2021 by dialing
1-800-770-2030 or 647-362-9199 and entering passcode 9884406.
The replay of the webcast will remain available
on the website until midnight, November 19, 2021.
About KP Tissue Inc. (KPT)KPT
was created to acquire, and its business is limited to holding, a
limited partnership interest in KPLP, which is accounted for as an
investment on the equity basis. KPT currently holds a 14.5%
interest in KPLP. For more information visit
www.kptissueinc.com.
About Kruger Products L.P.
(KPLP)KPLP is Canada's leading manufacturer of quality
tissue products for household, industrial and commercial use. KPLP
serves the Canadian consumer market with such well-known brands as
Cashmere®, Purex®, SpongeTowels®, Scotties® and White Swan®. In the
U.S., KPLP manufactures the White Cloud® brand, as well as many
private label products. The Away-From-Home division manufactures
and distributes high-quality, cost-effective product solutions to a
wide range of commercial and public entities. KPLP has
approximately 2,700 employees and operates nine FSC® COC-certified
(FSC® C-104904) production facilities in North America. For more
information visit www.krugerproducts.ca.
Non-IFRS MeasuresThis press
release uses certain non-IFRS financial measures which KPLP
believes provide useful information to management of KPLP and the
readers of the financial information in measuring the financial
performance and financial condition of KPLP. These measures do not
have a standardized meaning prescribed by IFRS and therefore may
not be comparable to similarly titled measures presented by other
companies. An example of such a measure is Adjusted EBITDA.
Beginning with Q4 2015 in accordance with Canadian Securities
Administrators Staff Notice 52-306 (Revised), we have referenced
Adjusted EBITDA as a non-IFRS financial measure. This term replaces
the previously referenced non-IFRS financial measure EBITDA.
Adjusted EBITDA is not a measurement of operating performance
computed in accordance with IFRS and should not be considered as a
substitute for operating income, net income or cash flows from
operating activities computed in accordance with IFRS. “Adjusted
EBITDA” is calculated by KPLP as net income (loss) before (i)
interest expense, (ii) income taxes, (iii) depreciation, (iv)
amortization, (v) impairment (gain on sale) of non-financial
assets, (vi) loss (gain) on disposal of property, plant and
equipment, (vii) foreign exchange loss (gain), (viii) costs related
to restructuring activities, (ix) changes in amortized cost of
Partnership units liability, (x) change in fair value of
derivatives, (xi) consulting costs related to operational
transformation initiatives, (xii) corporate development related
costs and (xiii) loss (gain) on sale of shares. A reconciliation of
Adjusted EBITDA to the relevant reported results can be found in
the MD&A of KPT and KPLP for the quarter ended September 30,
2021, available on SEDAR at www.sedar.com.
COVID-19In March 2020, the
World Health Organization characterized the outbreak of the novel
strain of coronavirus, specifically identified as “COVID-19” as a
global pandemic. There remains significant uncertainty as to the
duration and impact of the COVID-19 outbreak at this time. It is
not possible to reliably estimate or quantify the impact this
pandemic may have on the financial results and condition of KPLP in
future periods.
Forward-Looking
StatementsCertain statements in this press release about
KPT’s and KPLP's current and future plans, expectations and
intentions, results, levels of activity, performance, goals or
achievements or any other future events or developments constitute
forward-looking statements. Forward-looking statements in this
press release include, but are not limited to, the anticipated
benefits of the TAD Sherbrooke Project and the Sherbrooke Expansion
Project and the expected dates for commencement of construction and
production of the Sherbrooke Expansion Project. The words "may",
"will", "would", "should", "could", "expects", "plans", "intends",
"trends", "indications", "anticipates", "believes", "estimates",
"predicts", "likely" or "potential" or the negative or other
variations of these words or other comparable words or phrases, are
intended to identify forward-looking statements. The
forward-looking statements are based on certain key expectations
and assumptions made by KPT or KPLP. Although KPT and KPLP believe
that the expectations and assumptions on which such forward-looking
information is based are reasonable, undue reliance should not be
placed on the forward-looking statements since no assurance can be
given that such expectations and assumptions will prove to be
correct.
The outlook provided in respect of Adjusted
EBITDA for Q4 2021 is forward-looking information and is subject to
the risk and uncertainties referred to below. The purpose of the
outlook is to provide the reader with an indication of management’s
expectations, at the date of this press release, regarding KPLP’s
future financial performance. Readers are cautioned that this
information may not be appropriate for other purposes.
Many factors could cause KPLP’s actual results,
level of activity, performance or achievements or future events or
developments (which could in turn affect the economic benefits
derived from KPT’s economic interest in KPLP) to differ materially
from those expressed or implied by the forward-looking statements,
including, without limitation, the following factors, which are
discussed in greater detail in the “Risk Factors – Risks Related to
KPLP’s Business” section of the KPT Annual Information Form dated
March 11, 2021 available on SEDAR at www.sedar.com (the Annual
Information Form), except for the risks associated with the
Sherbrooke Expansion Project, which are discussed in greater detail
in Risk Factors in the MD&A of KPT and KPLP for the 3-month and
9-month periods ended September 30, 2021 available on SEDAR at
www.sedar.com: Kruger Inc.’s influence over KPLP; KPLP’s reliance
on Kruger Inc.; consequences of an event of insolvency relating to
Kruger Inc.; risks associated with the TAD Sherbrooke Project;
operational risks; significant increases in input costs; reduction
in supply of fibre; increased pricing pressure and intense
competition; KPLP’s inability to innovate effectively; adverse
economic conditions; dependence on key retail trade customers;
damage to the reputation of KPLP or KPLP’s brands; KPLP’s sales
being less than anticipated; KPLP’s failure to implement its
business and operating strategies; KPLP’s obligation to make
regular capital expenditures; KPLP’s entering into unsuccessful
acquisitions; KPLP’s dependence on key personnel; KPLP’s inability
to retain its existing customers or obtain new customers; KPLP’s
loss of key suppliers; KPLP’s failure to adequately protect its
intellectual property rights; KPLP’s reliance on third party
intellectual property licenses; adverse litigation and other claims
affecting KPLP; material expenditures due to comprehensive
environmental regulation affecting KPLP’s cash flow; KPLP’s pension
obligations are significant and can be materially higher than
predicted if KPLP Management’s underlying assumptions are
incorrect; labour disputes adversely affecting KPLP’s cost
structure and KPLP’s ability to run its plants; exchange rate and
U.S. competitors; KPLP’s inability to service all of its
indebtedness; exposure to potential consumer product liability;
covenant compliance; interest rate and refinancing risk;
information technology; cyber-security; insurance; internal
controls; trade related; and risk related to COVID-19.
Readers should not place undue reliance on
forward-looking statements made herein. The forward-looking
information contained herein is expressly qualified in its entirety
by this cautionary statement. The forward-looking information
contained herein is made as of the date of press release and KPT
undertakes no obligation to publicly update such forward-looking
information to reflect new information, subsequent or otherwise,
unless required by applicable securities laws.
INFORMATION:
Francois ParoyanGeneral Counsel and Corporate
SecretaryKP Tissue Inc.Tel.:
905.812.6936francois.paroyan@krugerproducts.ca
INVESTORS:
Mike BaldesarraDirector of Investor RelationsKP
Tissue Inc. Tel.: 905.812.6962IR@KPTissueinc.com
|
Kruger
Products L.P. |
|
Unaudited
Condensed Consolidated Statements of Financial
Position |
|
(thousands
of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
2021 |
|
December 31,
2020 |
|
|
$ |
|
$ |
Assets |
|
|
|
Current assets |
|
|
|
|
Cash, cash equivalents and restricted cash |
118,639 |
|
|
128,739 |
|
|
Trade and
other receivables |
98,827 |
|
|
88,041 |
|
|
Receivables
from related parties |
1,076 |
|
|
13 |
|
|
Advances to
partners |
9,937 |
|
|
5,647 |
|
|
Inventories |
258,189 |
|
|
215,934 |
|
|
Income tax
recoverable |
505 |
|
|
358 |
|
|
Prepaid
expenses |
8,243 |
|
|
8,315 |
|
|
|
495,416 |
|
|
447,047 |
|
Non-current assets |
|
|
|
|
Property,
plant and equipment |
1,207,540 |
|
|
1,194,191 |
|
|
Right-of-use
assets |
107,002 |
|
|
107,633 |
|
|
Other
long-term assets |
40,364 |
|
|
10 |
|
|
Goodwill |
152,021 |
|
|
152,021 |
|
|
Intangible
assets |
30,084 |
|
|
26,205 |
|
|
Deferred
income taxes |
33,383 |
|
|
24,217 |
|
Total assets |
2,065,810 |
|
|
1,951,324 |
|
|
|
|
|
|
Liabilities |
|
|
|
Current liabilities |
|
|
|
|
Trade and
other payables |
231,904 |
|
|
332,072 |
|
|
Payables to
related parties |
7,429 |
|
|
9,097 |
|
|
Income tax
payable |
371 |
|
|
554 |
|
|
Distributions payable |
12,202 |
|
|
11,919 |
|
|
Current
portion of provisions |
3,192 |
|
|
4,913 |
|
|
Current
portion of long-term debt |
39,205 |
|
|
9,495 |
|
|
Current
portion of lease liabilities |
30,175 |
|
|
25,341 |
|
|
|
324,478 |
|
|
393,391 |
|
Non-current liabilities |
|
|
|
|
Long-term
debt |
915,142 |
|
|
743,978 |
|
|
Long-term
lease liabilities |
99,799 |
|
|
105,634 |
|
|
Long-term
payable to related party |
41,777 |
|
|
- |
|
|
Long-term
provisions |
8,885 |
|
|
9,549 |
|
|
Other
long-term liabilities |
- |
|
|
575 |
|
|
Pensions |
26,972 |
|
|
161,333 |
|
|
Post-retirement benefits |
57,747 |
|
|
63,038 |
|
|
Liabilities to non-unitholders |
1,474,800 |
|
|
1,477,498 |
|
|
Current
portion of Partnership units liability |
14,132 |
|
|
31,244 |
|
|
Long-term
portion of Partnership units liability |
164,040 |
|
|
154,180 |
|
|
Total Partnership units liability |
178,172 |
|
|
185,424 |
|
Total liabilities |
1,652,972 |
|
|
1,662,922 |
|
|
|
|
|
|
Equity |
|
|
|
|
Partnership
units |
455,939 |
|
|
439,571 |
|
|
Deficit |
(116,504 |
) |
|
(224,503 |
) |
|
Accumulated
other comprehensive income |
73,403 |
|
|
73,334 |
|
Total equity |
412,838 |
|
|
288,402 |
|
Total equity and liabilities |
2,065,810 |
|
|
1,951,324 |
|
|
|
|
|
|
Kruger
Products L.P. |
Unaudited
Condensed Consolidated Statements of Comprehensive
Income |
(thousands
of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3-month |
|
3-month |
|
9-month |
|
9-month |
|
period
ended |
|
period
ended |
|
period
ended |
|
period
ended |
|
September 30,
2021 |
|
September 30,
2020 |
|
September 30,
2021 |
|
September 30,
2020 |
|
$ |
|
$ |
|
$ |
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue |
391,392 |
|
|
369,103 |
|
|
1,041,132 |
|
|
1,131,012 |
|
|
|
|
|
|
|
|
|
Expenses |
|
|
|
|
|
|
|
Cost of sales |
345,577 |
|
|
307,733 |
|
|
903,885 |
|
|
932,255 |
|
Selling, general and administrative
expenses |
29,055 |
|
|
31,267 |
|
|
86,404 |
|
|
91,393 |
|
Loss on sale of non-financial
assets |
2 |
|
|
- |
|
|
5 |
|
|
1 |
|
Restructuring costs, net |
166 |
|
|
52 |
|
|
207 |
|
|
1,273 |
|
|
|
|
|
|
|
|
|
Operating income |
16,592 |
|
|
30,051 |
|
|
50,631 |
|
|
106,090 |
|
|
|
|
|
|
|
|
|
Interest expense |
18,740 |
|
|
9,746 |
|
|
47,925 |
|
|
31,659 |
|
Other expense |
11,728 |
|
|
2,477 |
|
|
10,781 |
|
|
10,629 |
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
(13,876 |
) |
|
17,828 |
|
|
(8,075 |
) |
|
63,802 |
|
|
|
|
|
|
|
|
|
Income taxes |
(4,618 |
) |
|
(627 |
) |
|
(7,823 |
) |
|
8,055 |
|
|
|
|
|
|
|
|
|
Net
income (loss) for the period |
(9,258 |
) |
|
18,455 |
|
|
(252 |
) |
|
55,747 |
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss) |
|
|
|
|
|
|
|
Items that will not be
reclassified to net income (loss): |
|
|
|
|
|
|
|
Remeasurements of pensions |
44,377 |
|
|
(4,142 |
) |
|
138,418 |
|
|
(40,797 |
) |
Remeasurements of post-retirement
benefits |
1,670 |
|
|
(439 |
) |
|
6,019 |
|
|
(3,827 |
) |
Items that may be
subsequently reclassified to net income (loss): |
|
|
|
|
|
|
|
Cumulative translation
adjustment |
7,441 |
|
|
(6,320 |
) |
|
69 |
|
|
7,907 |
|
|
|
|
|
|
|
|
|
Total other comprehensive income (loss) for the
period |
53,488 |
|
|
(10,901 |
) |
|
144,506 |
|
|
(36,717 |
) |
|
|
|
|
|
|
|
|
Comprehensive income for the period |
44,230 |
|
|
7,554 |
|
|
144,254 |
|
|
19,030 |
|
|
|
|
|
|
|
|
|
Kruger
Products L.P. |
Unaudited
Condensed Consolidated Statements of Cash Flows |
(thousands
of Canadian dollars) |
|
|
|
|
|
|
|
|
|
9-month |
|
9-month |
|
period
ended |
|
period
ended |
|
September 30,
2021 |
|
September 30,
2020 |
|
$ |
|
$ |
Cash
flows from (used in) operating activities |
|
|
|
Net income (loss) for the period |
(252 |
) |
|
55,747 |
|
Items not
affecting cash |
|
|
|
Depreciation |
61,292 |
|
|
48,497 |
|
Amortization |
2,539 |
|
|
1,184 |
|
Loss on sale of property, plant and
equipment |
326 |
|
|
87 |
|
Change in amortized cost of
Partnership units liability |
10,283 |
|
|
10,903 |
|
Foreign exchange loss |
498 |
|
|
86 |
|
Change in fair value of
derivatives |
- |
|
|
(360 |
) |
Interest expense |
47,925 |
|
|
31,659 |
|
Pension and post-retirement
benefits |
12,486 |
|
|
11,121 |
|
Provisions |
1,547 |
|
|
6,137 |
|
Income taxes |
(7,823 |
) |
|
8,055 |
|
Loss on sale of non-financial
assets |
5 |
|
|
1 |
|
Total items not affecting cash |
129,078 |
|
|
117,370 |
|
|
|
|
|
Net change
in non-cash working capital |
(120,743 |
) |
|
27,086 |
|
Contributions to pension and post-retirement benefit plans |
(11,451 |
) |
|
(11,793 |
) |
Provisions
paid |
(4,173 |
) |
|
(2,054 |
) |
Income tax
payments |
(2,019 |
) |
|
(1,808 |
) |
Net
cash from (used in) operating activities |
(9,560 |
) |
|
184,548 |
|
|
|
|
|
Cash
flows from (used in) investing activities |
|
|
|
Purchases of
property, plant and equipment |
(19,438 |
) |
|
(12,758 |
) |
Purchases of
property, plant and equipment related to the TAD Sherbrooke
Project |
(88,273 |
) |
|
(194,118 |
) |
Interest
paid on credit facilities related to the TAD Sherbrooke
Project |
(608 |
) |
|
(7,167 |
) |
Purchases of
software |
(774 |
) |
|
(1,633 |
) |
Proceeds on
sale of shares |
- |
|
|
992 |
|
Proceeds on
sale of property, plant and equipment |
8 |
|
|
- |
|
Net
cash used in investing activities |
(109,085 |
) |
|
(214,684 |
) |
|
|
|
|
Cash
flows from (used in) financing activities |
|
|
|
Proceeds
from long-term debt |
225,197 |
|
|
193,538 |
|
Repayment of
long-term debt |
(21,913 |
) |
|
(84,520 |
) |
Payment of
deferred financing fees |
(8,935 |
) |
|
(500 |
) |
Payment of
lease liabilities |
(18,954 |
) |
|
(14,506 |
) |
Interest
paid on long-term debt |
(24,753 |
) |
|
(21,762 |
) |
Distributions and advances paid, net |
(41,360 |
) |
|
(18,372 |
) |
Net
cash from financing activities |
109,282 |
|
|
53,878 |
|
|
|
|
|
Effect of exchange rate changes on cash and
cash |
|
|
|
equivalents held in foreign
currency |
(737 |
) |
|
586 |
|
|
|
|
|
Increase (decrease) in cash, cash equivalents and
restricted cash during the period |
(10,100 |
) |
|
24,328 |
|
|
|
|
|
Cash, cash equivalents and restricted cash - Beginning of
period |
128,739 |
|
|
93,141 |
|
|
|
|
|
Cash, cash equivalents and restricted cash - End of
period |
118,639 |
|
|
117,469 |
|
|
|
|
|
Kruger
Products L.P. |
Segment and
Geographic Results |
(thousands
of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
3-month |
|
3-month |
|
9-month |
|
9-month |
|
|
period
ended |
|
period
ended |
|
period
ended |
|
period
ended |
|
|
September 30,
2021 |
|
September 30,
2020 |
|
September 30,
2021 |
|
September 30,
2020 |
|
|
$ |
|
$ |
|
$ |
|
$ |
|
|
|
|
|
|
|
|
|
Segment Information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment Revenue |
|
|
|
|
|
|
|
|
Consumer |
|
332,416 |
|
|
319,869 |
|
|
896,144 |
|
|
971,400 |
|
AFH |
|
58,976 |
|
|
49,234 |
|
|
144,988 |
|
|
159,612 |
|
|
|
|
|
|
|
|
|
|
Total
segment revenue |
|
391,392 |
|
|
369,103 |
|
|
1,041,132 |
|
|
1,131,012 |
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA |
|
|
|
|
|
|
|
|
Consumer |
|
39,092 |
|
|
55,264 |
|
|
123,563 |
|
|
179,193 |
|
AFH |
|
2,162 |
|
|
(3,466 |
) |
|
(3,174 |
) |
|
(6,632 |
) |
Corporate and other costs |
|
(941 |
) |
|
(5,550 |
) |
|
(5,296 |
) |
|
(10,939 |
) |
|
|
|
|
|
|
|
|
|
Total
Adjusted EBITDA |
|
40,313 |
|
|
46,248 |
|
|
115,093 |
|
|
161,622 |
|
|
|
|
|
|
|
|
|
|
Reconciliation to Net income (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation
and amortization |
|
23,464 |
|
|
15,948 |
|
|
63,831 |
|
|
49,681 |
|
Interest
expense |
|
18,740 |
|
|
9,746 |
|
|
47,925 |
|
|
31,659 |
|
Change in
amortized cost of Partnership units liability |
|
3,427 |
|
|
5,863 |
|
|
10,283 |
|
|
10,903 |
|
Change in
fair value of derivatives |
|
- |
|
|
- |
|
|
- |
|
|
(360 |
) |
Loss on sale
of property, plant and equipment |
|
62 |
|
|
38 |
|
|
326 |
|
|
87 |
|
Loss on sale
of non-financial assets |
|
2 |
|
|
- |
|
|
5 |
|
|
1 |
|
Restructuring costs, net |
|
166 |
|
|
52 |
|
|
207 |
|
|
1,273 |
|
Foreign
exchange (gain) loss |
|
8,301 |
|
|
(3,386 |
) |
|
498 |
|
|
86 |
|
Corporate
development related costs |
|
27 |
|
|
159 |
|
|
93 |
|
|
159 |
|
Consulting
costs related to operational transformation initiatives |
|
- |
|
|
- |
|
|
- |
|
|
4,331 |
|
|
|
|
|
|
|
|
|
|
Income
(loss) before income taxes |
|
(13,876 |
) |
|
17,828 |
|
|
(8,075 |
) |
|
63,802 |
|
|
|
|
|
|
|
|
|
|
Income
taxes |
|
(4,618 |
) |
|
(627 |
) |
|
(7,823 |
) |
|
8,055 |
|
|
|
|
|
|
|
|
|
|
Net income
(loss) |
|
(9,258 |
) |
|
18,455 |
|
|
(252 |
) |
|
55,747 |
|
|
|
|
|
|
|
|
|
|
Geographic Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Canada |
|
233,529 |
|
|
223,272 |
|
|
647,516 |
|
|
671,805 |
|
US |
|
157,863 |
|
|
145,831 |
|
|
393,616 |
|
|
459,207 |
|
|
|
|
|
|
|
|
|
|
Total
revenue |
|
391,392 |
|
|
369,103 |
|
|
1,041,132 |
|
|
1,131,012 |
|
|
|
|
|
|
|
|
|
|
KP Tissue
Inc. |
Unaudited
Condensed Statements of Financial Position |
(thousands
of Canadian dollars) |
|
|
|
|
|
|
|
|
|
September 30,
2021 |
|
December 31,
2020 |
|
$ |
|
$ |
Assets |
|
|
|
|
|
|
|
Current assets |
|
|
|
Distributions receivable |
1,774 |
|
|
1,755 |
|
Receivable from Partnership |
- |
|
|
21 |
|
Income tax recoverable |
106 |
|
|
- |
|
|
1,880 |
|
|
1,776 |
|
|
|
|
|
Non-current assets |
|
|
|
Investment in associate |
80,017 |
|
|
69,537 |
|
|
|
|
|
Total Assets |
81,897 |
|
|
71,313 |
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
Current liabilities |
|
|
|
Dividend payable |
1,774 |
|
|
1,755 |
|
Payable to Partnership |
74 |
|
|
- |
|
Current portion of advances from Partnership |
1,478 |
|
|
874 |
|
Income tax payable |
- |
|
|
1,722 |
|
|
3,326 |
|
|
4,351 |
|
Non-current liabilities |
|
|
|
Deferred income taxes |
1,022 |
|
|
634 |
|
|
|
|
|
Total liabilities |
4,348 |
|
|
4,985 |
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
Common shares |
21,471 |
|
|
20,355 |
|
Contributed surplus |
144,819 |
|
|
144,819 |
|
Deficit |
(101,760 |
) |
|
(111,907 |
) |
Accumulated other comprehensive income |
13,019 |
|
|
13,061 |
|
|
|
|
|
Total equity |
77,549 |
|
|
66,328 |
|
|
|
|
|
Total liabilities and equity |
81,897 |
|
|
71,313 |
|
|
|
|
|
KP Tissue
Inc. |
Unaudited
Condensed Statements of Comprehensive Income (Loss) |
(thousands
of Canadian dollars, except share and per share
amounts) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3-month
period ended September 30, 2021 |
|
3-month
period ended September 30, 2020 |
|
9-month
period ended September 30, 2021 |
|
9-month
period ended September 30, 2020 |
|
$ |
|
$ |
|
$ |
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity income (loss) |
(2,686 |
) |
|
1,355 |
|
|
(4,033 |
) |
|
4,155 |
|
Dilution
gain |
81 |
|
|
77 |
|
|
243 |
|
|
528 |
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
(2,605 |
) |
|
1,432 |
|
|
(3,790 |
) |
|
4,683 |
|
|
|
|
|
|
|
|
|
Income taxes |
(382 |
) |
|
667 |
|
|
(1,542 |
) |
|
2,340 |
|
|
|
|
|
|
|
|
|
Net
income (loss) for the period |
(2,223 |
) |
|
765 |
|
|
(2,248 |
) |
|
2,343 |
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss) |
|
|
|
|
|
|
|
net of tax expense (recovery) |
|
|
|
|
|
|
|
Items that will not be reclassified to
net income (loss): |
|
|
|
|
|
|
|
Remeasurements of pensions |
5,600 |
|
|
(355 |
) |
|
17,152 |
|
|
(4,010 |
) |
Remeasurements of post-retirement benefits |
147 |
|
|
(39 |
) |
|
536 |
|
|
(348 |
) |
Items that may be subsequently
reclassified to net income (loss): |
|
|
|
|
|
|
|
Cumulative translation adjustment |
1,092 |
|
|
(1,003 |
) |
|
(42 |
) |
|
1,128 |
|
|
|
|
|
|
|
|
|
Total other comprehensive income (loss) for the
period |
6,839 |
|
|
(1,397 |
) |
|
17,646 |
|
|
(3,230 |
) |
|
|
|
|
|
|
|
|
Comprehensive income (loss) for the period |
4,616 |
|
|
(632 |
) |
|
15,398 |
|
|
(887 |
) |
|
|
|
|
|
|
|
|
Basic earnings (loss) per share |
(0.23 |
) |
|
0.08 |
|
|
(0.23 |
) |
|
0.24 |
|
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding |
9,853,722 |
|
|
9,721,047 |
|
|
9,817,280 |
|
|
9,688,788 |
|
|
|
|
|
|
|
|
|
KP Tissue
Inc. |
Unaudited
Condensed Statement of Cash Flows |
(thousands
of Canadian dollars) |
|
|
|
|
|
|
|
|
|
9-month
period ended September 30, 2021 |
|
9-month
period ended September 30, 2020 |
|
$ |
|
$ |
Cash
flows from (used in) operating activities |
|
|
|
Net income (loss) for the period |
(2,248 |
) |
|
2,343 |
|
Items not
affecting cash |
|
|
|
Equity (income) loss |
4,033 |
|
|
(4,155 |
) |
Dilution gain |
(243 |
) |
|
(528 |
) |
Income taxes |
(1,542 |
) |
|
2,340 |
|
Total items not affecting cash |
2,248 |
|
|
(2,343 |
) |
|
|
|
|
Net change
in non-cash working capital |
95 |
|
|
94 |
|
Tax
payments |
(3,311 |
) |
|
(1,504 |
) |
Tax
Distribution received |
1,738 |
|
|
781 |
|
Advances
received |
1,478 |
|
|
629 |
|
|
|
|
|
Net
cash from (used in) operating activities |
- |
|
|
- |
|
|
|
|
|
Cash
flows from investing activities |
|
|
|
Partnership
unit distributions received |
4,158 |
|
|
4,193 |
|
|
|
|
|
Net
cash from investing activities |
4,158 |
|
|
4,193 |
|
|
|
|
|
Cash
flows used in financing activities |
|
|
|
Dividends
paid |
(4,158 |
) |
|
(4,193 |
) |
|
|
|
|
Net
cash used in financing activities |
(4,158 |
) |
|
(4,193 |
) |
|
|
|
|
Increase (decrease) in cash and cash equivalents during the
period |
- |
|
|
- |
|
|
|
|
|
Cash
and cash equivalents - Beginning of period |
- |
|
|
- |
|
|
|
|
|
Cash
and cash equivalents - End of period |
- |
|
|
- |
|
KP Tissue (TSX:KPT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
KP Tissue (TSX:KPT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024